Genentech (RHHBY) Says Phase III Study of Lampalizumab for Geographic Atrophy Didn’t Meet Primary Endpoint – StreetInsider.com

Genentech (RHHBY) Says Phase III Study of Lampalizumab for Geographic Atrophy Didn’t Meet Primary Endpoint – StreetInsider.com

Genentech (RHHBY) Says Phase III Study of Lampalizumab for Geographic Atrophy Didn’t Meet Primary Endpoint – StreetInsider.com
Published on 2017-09-08